Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients

Autor(es)

Moura, Andrew D. ^[1] ; da Costa, Hernan H. M. ^[1] ; Correa, Victor A. ^[1] ; Lima, Ana K. de S. ^[2] ; Lindoso, Jose A. L. ^{[3, 2, 4]} ; De Gaspari, Elizabeth ^[1] ; Hong, Marisa A. ^[1] ; Cunha-Junior, Jair P. ^[5] ; Prudencio, Carlos R. ^[1]

Afiliação do(s) autor(es)

^[1] Adolfo Lutz Inst, Ctr Immunol, Sao Paulo - Brazil

^[2] Inst Infectol Emilio Ribas, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo - Brazil

^[4] Inst Trop Med, Lab Protozool, Sao Paulo - Brazil

^[5] Univ Fed Uberlandia, Dept Immunol, Lab Immunochem & Immunotechnol, Uberlandia, MG - Brazil

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 11, n. 1 SEP 3 2021.
• Citações Web of Science: 1

Resumo

SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefined. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specificity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 8-14 and 15-21 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P < 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the first weeks of symptoms onset. Our findings constitute the effort to clarify IgG antibodies' kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more significant potential for life-threatening. (AU)

• Processo FAPESP: 17/50333-7 - Plano de desenvolvimento institucional em pesquisa do Instituto Adolfo Lutz (PDIp)
• Beneficiário: Carlos Henrique Camargo
• Modalidade de apoio: Auxílio à Pesquisa - Programa Modernização de Institutos Estaduais de Pesquisa
• Processo FAPESP: 18/04202-0 - Estudo da imunogenicidade de antígenos de membrana externa de Neisseria meningitidis e interação com lípides catiônicos: avaliação de novo adjuvante para Neisseria meningitidis em diferentes linhagens de camundongos idosos
• Beneficiário: Elizabeth Natal de Gaspari
• Modalidade de apoio: Auxílio à Pesquisa - Regular